ABBV · News · 20260821N

Oncology Pipeline Progress

AbbVie Inc. · 2026-08-21 · Importance 31 · Surprise 42

AbbVie will present new clinical data at the 2026 World Conference on Lung Cancer (WCLC) across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The portfolio includes investigational ABBV-1480 (RC148), a PD-1/VEGF bispecific antibody, telisotuzumab adizutecan (Temab-A), and ABBV-706. Reported data include a 90% objective response rate for ABBV-1480 plus chemotherapy in squamous NSCLC, while the programs remain unapproved and their commercial potential depends on larger-trial efficacy and safety results. The disclosures support AbbVie's strategy of expanding beyond immunology and neuroscience into next-generation immunotherapies, targeted antibody-drug conjugates, and combination approaches.

Key facts

• Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation. source
• AbbVie will share new data and updates from its telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). source
• ABBV-1480 plus chemotherapy produced a 90% objective response rate in squamous NSCLC. source
• AbbVie announced these WCLC presentations on Aug. 21, 2026. source